From: Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study
Continuation
n = 19, n (%)
Interruption
n = 18, n (%)
Total
n = 37, n (%)
IHD
12
(63%)
7
(39%)
19
(51)
AF
5
(26%)
6
(33%)
11
(30)
CI
0
(0%)
(16)
Primary prevention
2
(11%)
1
(6%)
3
(8)
Others
(16%)